MedTrace Logo

Early Pharmacological and Immune Monitoring After Conversion to Belatacept in Renal Transplant Patients

NCT05632523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-08-11

No results posted yet for this study

Summary

Single-center, prospective, translational, clinical-biological, multidisciplinary study

Conditions

  • Renal Transplant
  • Conversion

Interventions

OTHER

Blood sample

Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion

OTHER

urinary sample

Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Philippe GATAULT · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2024-11-06
Completion
2024-11-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05632523 on ClinicalTrials.gov